Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta Plus Study: 161Tb-DOTA-LM3 vs 177Lu-DOTATOC in GEP-NET
NCT05359146Phase 1Recruiting
- Sponsor
- University Hospital Basel
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 161Tb-DOTA-LM3 in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (4 arms), sponsored by University Hospital Basel. Primary endpoints: Change in bone marrow doses at 168 hours and Change in kidney doses at 168 hours. Started Mar 2023; status: recruiting.
02
Drugs
161Tb-DOTA-LM3
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05359146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359146.